Study Design. A meta-analysis of randomized controlled trials (RCTs).
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In addition, supplemental low-dose ketamine can be used for analgesia. 3 In general, adjuvant perioperative ketamine has been reported to reduce morphine consumption in the first 24 hours following surgery with little to no adverse events. 4 Vague feelings, blurred vision, and hallucinations are the adverse events most commonly encountered. 1 Ketamine may be administered as a single-dose, continuous intravenous (IV) infusion, IV patient-controlled analgesia (IV-PCA), or epidural infusion. 2 It may be administered preoperatively, intraoperatively, and/or postoperatively. 1 Although supplemental ketamine has been studied broadly in a variety of procedures and operations, there is no consensus regarding the effectiveness of adjunctive ketamine analgesic use specifically in spine surgery. Thus, the primary objective of this study was to determine whether perioperative low-dose ketamine reduced opioid consumption after spine surgery. Secondary goals included determining if ketamine use affected postoperative pain scores and if administration of ketamine was linked to higher rates of complications.
MATERIALS AND METHODS

Systematic Search
A systematic search strategy was designed and tailored to each database with the help of a medical librarian. The
Inclusion and Exclusion Criteria
Inclusion and exclusion criteria were defined and agreed upon by all authors a priori. Articles that met the following criteria were eligible for inclusion in the meta-analysis: (1) the article described a human study; (2) ketamine was administered; (3) elective, inpatient spine surgery was performed; (4) the article described a RCT; (5) postoperative analgesia was reported; (6) postoperative pain scores were reported; (7) postoperative complications were reported; (8) general anesthesia was administered. Articles that met any of the following exclusion criterion were excluded from the meta-analysis: (1) the article described a nonhuman study; (2) ketamine was only administered for general anesthesia; (3) trauma, outpatient, or nonspine surgery was conducted; (4) the article did not describe a clinical trial; (5) postoperative analgesia was not reported; (6) postoperative pain scores were not reported; (7) general anesthesia was not administered; (8) a treatment or control arm of the trial comprised 10 patients or fewer; (9) non-English language article. The results were updated as of February 4, 2015.
Article Screening
Duplicate articles were removed from the results of the systematic search of each database. The remaining titles and abstracts were downloaded and screened independently by two authors (A.P. and S.F.) on the basis of the pre-existing inclusion and exclusion criteria. A third author (M.E.) resolved disagreement. The full texts of the articles were then screened independently by A.P. and S.F. and disputes once again resolved by M.E. Kappa scores were used to quantify inter-rater agreement. All articles remaining after the second round of screening were included in the meta-analysis.
Data Abstraction
Data were abstracted from the included studies by one author (A.P.). The corresponding author of each study was contacted individually for additional raw or grouped data; data requests were granted by the corresponding authors of two studies. 5, 6 The following study characteristics were recorded: first author, publication year, and number of subjects. Also, the mode, dosage, and timing of ketamine administration were documented. Other recorded data included placebo control (saline) and the primary postoperative analgesic. Outcomes were only analyzed if reported by at least three studies. Continuous outcomes included opioid consumption and postoperative pain scores at rest. Dichotomous outcomes included adverse events such as bad dreams, cardiac events, dysphoria, hallucinations, headache, postoperative nausea and vomiting (PONV), pruritus, psychotomimetic effects, respiratory depression, sedation, and urinary retention. In articles that reported more than one treatment arm, treatment arms were combined to create a single pair-wise comparison as described by Higgins and Green. 7 
Data Normalization
With the help of biostatisticians, abstracted data were normalized before analysis. Opioid consumption was analyzed after converting all nonmorphine primary postoperative analgesics such as fentanyl (100:1 potency 8 ) and hydromorphone (5:1 potency 9 ) to morphine equivalents. This was necessary for five studies. [10] [11] [12] [13] [14] Due to differences in the reporting of opioid consumption, estimation of the average cumulative morphine equivalent consumption was necessary for several studies. In four studies, we standardized weight-adjusted means and standard deviations by multiplying by average weight and using the product of the variances to produce a crude estimate of the standard deviation. 6, 10, 15, 16 In one study, the cumulative opioid consumption was estimated from infusion rate. 15 In trials that did not report cumulative opioid consumption but described opioids consumed over select time periods (e.g., 0-24, 24-48 hours, and so on), the average cumulative analgesic was calculated and the standard deviations were imputed by entering the largest available standard deviations, thereby producing a conservative estimate. A series of sensitivity analyses were conducted to determine the effect of these estimations.
At rest, pain scores were reported on a 0 to 10 scale by eight studies, 6, 11, 13, [15] [16] [17] [18] [19] 0 to 5 scale by two studies, 20, 21 and 0 to 100 scale by four studies. 5, 10, 13, 14 Means and standard deviations of pain scores were normalized to a 0 to 10 scale before comparison.
Normalization was required for the following dichotomous outcomes: unpleasant dreams, cardiac events, dysphoria, hallucinations, PONV, and sedation. PONV was reported as a combined event in five studies and separately (experiences of nausea and/or number of emesis) in three studies. In the latter case, the incidence of vomiting was recorded preferentially. Cardiac events included arrhythmia, circulatory depression, and/or major changes in heart rate or blood pressure. Several studies (n ¼ 3) reported dysphoria, while seven reported unpleasant dreams and eight reported hallucinations separately. Although sedation was analyzed as a dichotomous outcome, sedation was reported as a continuous outcome in three articles. In such cases, the corresponding author was contacted for additional data; supplementary data were obtained for two studies. Sedation was recorded for any score of 5 or above (on a 0-5 scale), mention of deep sedation, and/or description of response only with any, repeated, or painful stimuli in accordance with guidelines established by the American Society of Anesthesiologists (ASA). 22 
Statistical Analysis
Microsoft Excel for Mac Version 15.11.12 and Review Manager 5.3.5 for Mac were used to conduct the analysis. 23 The Cochrane Handbook was used as a reference. 7 For continuous outcomes such as opioid consumption, postoperative pain scores, and length of stay, mean differences (MDs) and 95% confidence intervals (CIs) were calculated. Odds ratio (OR) and 95% CI were calculated for dichotomous outcomes (adverse events). Chi-squared analysis was used to test for heterogeneity between studies with a significance value set at 0.10 in order to more accurately detect significant heterogeneity. 24 Heterogeneity was further quantified by applying the I 2 test with values exceeding 50% indicating considerable or substantial heterogeneity. 7 The random effects model was used to incorporate betweenstudies heterogeneity for comparisons with P hetero < 0.10 and I 2 > 50%; otherwise, the fixed effects model was used. 7 Before incorporating supplementary data obtained from corresponding authors, sensitivity analyses were conducted.
RESULTS
Systematic Search and Article Screening
The systematic search yielded 1846 articles from PubMed (n ¼ 618), Web of Science (n ¼ 413), Scopus (n ¼ 208), and the Cochrane Central Register of Controlled Trials (n ¼ 607). A total of 696 duplicate publications were removed. The remaining 1150 articles were reviewed by title and abstract such that 1127 were excluded (k ¼ 0.6). The remaining 23 articles were screening for eligibility on the basis of full-text review. Another nine articles were discarded and a final tally of 14 articles were included in the qualitative and quantitative synthesis (k ¼ 0.5). Figure 1 diagrams the article screening process.
Included Studies
A total of 14 RCTs comprising 649 patients were included in the meta-analysis. Study characteristics are provided in Table 1 .
Morphine Equivalent Consumption
Postoperative morphine equivalent consumption and postoperative pain scores are documented in 
Adverse Events
Adverse events are documented in 
DISCUSSION
Ketamine has been discussed in the literature extensively as a supplemental analgesic for perioperative pain control. Although several reviews have reported a statistically significant decrease in opioid analgesic consumption with use of ketamine, whether this holds true for spine surgery is not certain. 4, 25 According to the findings of this meta-analysis, addition of supplemental ketamine yielded a significant reduction in postoperative morphine equivalent consumption at 4, 8, 12, and 24 hours postoperatively. However, this statistically significant opioid-sparing effect was no longer apparent at 36 hours following surgery. By 48 hours after surgery, patients who had been administered ketamine actually had a greater cumulative opioid consumption than their counterparts, though this was not considered statistically significant.
With regards to postoperative pain, patients in the ketamine group reported lower pain scores, on average, throughout the postoperative period (at 0, 1, 6, 12, 24, 36, 48, and 72 hours after surgery). Although the difference in pain scores immediately after surgery (0-1 hour) was not significant, patients in the ketamine reported significantly lower average pain scores at 6, 12, and 24 hours following surgery. This reduction in pain scores mirrors the reduction in cumulative morphine equivalent consumption during the first postoperative day. In addition, any difference in pain scores after 24 hours (36, 48, and 72 hours after surgery) was not significant. As a result, the significant reduction in morphine equivalent consumption by patients in the ketamine group during the first 24 hours following surgery coincided with significantly reduced pain scores during that same period, with the exception of the first postoperative hour. These findings suggest that the analgesia provide by supplemental low-dose ketamine may be confined to the first 24 hours following spine surgery.
Notably, this meta-analysis showed the opiate-sparing effects and postoperative pain reduction due to ketamine demonstrated efficacy exclusively within the first 24 hours postoperatively. This ''window effect'' may stem from differences in timing, dose, or mode of ketamine among trials. For example, ketamine was administered solely intraoperatively in several trials; given that the half-life of ketamine is approximately 186 minutes, analgesic effects may dissipate soon after intraoperative infusion is terminated. 26 Another possible explanation may be dosing: Pestieau et al. 16 reduced ketamine dosage when transitioning from the intraoperative to postoperative period. Furthermore, in several trials, continuous IV infusions during the intraoperative period were replaced by IV-PCA postoperatively, introducing variables such as patient decision-making and differences in lockout intervals. Finally, opiate-tolerant patients may respond differently to ketamine, most notably at 48 hours and beyond. For example, Subramaniam et al.
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included subjects with preoperative opiate use, finding lowdose ketamine to be ineffective. Although many trials excluded patients with preoperative narcotic use, others did not acknowledge preoperative opiate consumption, leaving it unclear as to whether opiate tolerant patients were included and if so, how many. As a result, if chronic opiate use mitigated ketamine analgesia, the magnitude of this effect is indeterminate with the available data to include.
Delirium has been reported to occur in 5% to 15% of patients undergoing noncardiac surgery and ketamine has been noted to cause delirium. 27, 28 Although delirium was not explicitly reported by the trials included in this metaanalysis, several adverse events commonly associated with delirium were studied: unpleasant dreams, hallucinations, psychotomimetic events, and dysphoria. None of the aforementioned complications achieved statistical significance. These findings are contrary to previous reports. For example, ketamine as an anesthetic agent has been associated with dysphoria in as many as 10% to 20% of adult patients after a variety of surgical procedures. 29 However, subanesthetic doses of ketamine, such as those that may be used for supplemental analgesia, have been reported to reduce the occurrence of dysphoria. Also, ketamine has previously been associated with a reduction in PONV, though no such difference was detected in this study. 4, 30 In terms of cardiac events, headaches, respiratory depression, and urinary retention, there were no significant differences between groups.
Recent trends in spine surgery involve eschewing opiates in favor of nonopiate agents due to suboptimal opiaterelated side effects. 2 One such nonopiate agent is ketamine, which has been noted to prevent opiate-induced hyperalgesia, the paradoxical heightened sensitive to pain following opiate exposure. 31, 32 Given the short-term reduction in both morphine equivalent consumption and postoperative pain scores without an increase in complication rates, this metaanalysis offers an informed choice with new knowledge supporting either use or nonuse of ketamine in the perioperative period based on individual interpretation of the objective results.
Limitations
Despite an exhaustive and systematic search of multiple databases, it is possible that there exist trials of ketamine use that were not included in this study. Furthermore, of the trials that were included, there was often significant heterogeneity in the comparisons. For example, the modes of administration included single bolus (n ¼ 9), continuous infusion (n ¼ 10), and IV-PCA (n ¼ 5). Dosages also differed considerably, weight-adjusted doses were utilized in several trials (n ¼ 4), and timing of administration varied from intraoperatively (n ¼ 4), postoperatively (n ¼ 2) trials, and both intra-and postoperatively (n ¼ 8). This study was not designed to evaluate dose-dependency, so although supplemental ketamine yielded a significant reduction in morphine equivalent consumption for the first 24 hours, the optimal dose remains unclear. Furthermore, combining low-and high-dose treatment arms may have produced a moderating effect. Similarly, this meta-analysis was not structured to compare the mode or timing of ketamine administration, but determining the optimal dose and/or the ideal timing of IV ketamine may constitute avenues for future prospective studies. Although none of the adverse events obtained statistical significance, it is possible that this study was not adequately powered to detect differences in complication rates as evidence by several instances in which either the ketamine group or control contained no patients who experienced a complication.
CONCLUSION
This meta-analysis of supplemental ketamine for analgesia in spine surgery found a consistent opioid analgesic sparing effect over the course of 24 hours following surgery. With the exception of the first hour, this reduction in analgesic consumption coincided with significant reduced pain scores. Notably, significant reductions in both morphine equivalent consumption and pain scores did not persist beyond the first 24 hours, suggesting that the analgesic effect of supplemental ketamine may be limited to this timeframe. Furthermore, there was significant heterogeneity associated with the trials that were included in this study. Although this study indicates that low-dose supplemental ketamine may be useful for short-term analgesia following spine surgery, this metaanalysis was not designed to evaluate dose, timing, or mode of ketamine administration, all of which constitute avenues for future research.
Key Points
Supplemental ketamine reduced cumulative morphine equivalent consumption at 4, 8, 12, and 24 hours after spine surgery. Supplemental ketamine reduced postoperative pain scores at 6, 12, and 24 hours after spine surgery. Supplemental ketamine did not predispose spine surgery patients to an increased odds of experiencing unpleasant dreams, cardiac events, dysphoria, hallucinations, postoperative nausea or vomiting, pruritus, psychotomimetic events, respiratory depression, sedation, or urinary retention.
